Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.

[1]  J. Pearson,et al.  Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. , 2021, Cancer cell.

[2]  E. Jonasch,et al.  High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  S. Karam,et al.  Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response , 2021, Journal of translational medicine.

[4]  Amy K. Erbe,et al.  Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma , 2020, Frontiers in Immunology.

[5]  R. Tishler,et al.  Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. , 2020, JAMA oncology.

[6]  A. Lam,et al.  Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma , 2020, International Journal of Oral Science.

[7]  J. Blay,et al.  Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma , 2020, Oncotarget.

[8]  A. Stenzinger,et al.  Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project , 2020, Journal for ImmunoTherapy of Cancer.

[9]  Steffi Oesterreich,et al.  Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. , 2019, Immunity.

[10]  R. Ferris,et al.  Immunotherapy for head and neck cancer: Recent advances and future directions. , 2019, Oral oncology.

[11]  Jason M. Johnson,et al.  Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. , 2019, Journal of Clinical Oncology.

[12]  O. V. Matorin,et al.  Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study , 2019, The Lancet.

[13]  J. Galon,et al.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.

[14]  L. Alemany,et al.  Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[16]  V. Takiar,et al.  Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma. , 2018 .

[17]  Rajarsi R. Gupta,et al.  Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. , 2018, Cell reports.

[18]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[19]  T. Tramm,et al.  Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists , 2018, Acta oncologica.

[20]  J. Adam,et al.  TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma , 2018, ESMO Open.

[21]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[22]  E. King,et al.  Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space , 2017, Clinical Cancer Research.

[23]  J. Haanen.  Converting Cold into Hot Tumors by Combining Immunotherapies , 2017, Cell.

[24]  S. Lantuejoul,et al.  The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  P. Hammerman,et al.  Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. , 2017, Oral oncology.

[26]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[27]  J. Lunceford,et al.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.

[28]  Jaime Rodriguez-Canales,et al.  An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer , 2016, Clinical Cancer Research.

[29]  Genevera I. Allen,et al.  TCGA2STAT: simple TCGA data access for integrated statistical analysis in R , 2016, Bioinform..

[30]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[31]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[32]  A. Puisieux,et al.  Oncogenic roles of EMT-inducing transcription factors , 2014, Nature Cell Biology.

[33]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[34]  N. Futran,et al.  A 13-Gene Signature Prognostic of HPV-Negative OSCC: Discovery and External Validation , 2013, Clinical Cancer Research.

[35]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.